← back to search

David J. Fisher

MRC Clinical Trials Unit at UCL · GB
Area of research
Electrical and Electronic Engineering · Oncology
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Advancements in Photolithography Techniques, Silicon and Solar Cell Technologies, and Meta-analysis and systematic reviews.
h-index
62
citations
19,291
works
504
NIH funding
primary concept
Medicine
email

Recent publications

Intermediate- versus prophylactic-dose heparin for hospitalised patients with COVID-19: an updated meta-analysis of randomised trials.
2026cited by 0position: contributordoi
Treatment modifiers of interpersonal functioning in psychotherapy for people with borderline personality disorder: Systematic review with meta-analyses of individual participant data.
2026cited by 0position: contributordoi
Practical methods for incorporating summary time-to-event data into meta-analysis: updated guidance.
2025cited by 19position: contributordoi
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data
European Urology 2025cited by 13position: middledoi
Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) benefit more from androgen receptor pathway inhibitors (ARPIs)? STOPCAP meta-analyses of individual participant data (IPD).
Journal of Clinical Oncology 2025cited by 13position: firstdoi
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data.
2025cited by 7position: contributordoi
Anticoagulation Among Patients Hospitalized for COVID-19 : A Systematic Review and Prospective Meta-analysis.
2025cited by 4position: contributordoi
Developing a multivariable prediction model to support personalized selection among five major empirically-supported treatments for adult depression. Study protocol of a systematic review and individual participant data network meta-analysis.
2025cited by 3position: contributordoi
Treatment Moderators of Symptom Severity in Psychotherapy for People with Borderline Personality Disorder: Systematic Review with Meta-Analyses of Individual Participant Data
Psychotherapy and Psychosomatics 2025cited by 2position: contributordoi
Relationship between inherited genetic variation and survival from colorectal cancer stratified by tumour location.
2025cited by 2position: contributordoi
Reply to Shenglong Li and Cuicui Wang's Letter to the Editor re: Sarah Burdett, David J. Fisher, Jayne F. Tierney, et al. Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data. Eur Urol 2025;88:277-90.
2025cited by 0position: contributordoi
Correction: Anticoagulation Among Patients Hospitalized for COVID-19.
2025cited by 0position: contributordoi
Evaluating surrogates for overall survival in the adjuvant treatment of bladder cancer with chemotherapy.
2025cited by 0position: contributordoi
Treatment options for women with heavy menstrual bleeding: a protocol for comprehensive systematic review, network meta-analyses and health economic assessment.
2025cited by 0position: contributordoi
Efficacy and moderators of efficacy of cognitive behavioural therapies with a trauma focus in children and adolescents: an individual participant data meta-analysis of randomised trials.
2024cited by 19position: contributordoi
Sodium-glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials.
2024cited by 9position: contributordoi
Effectiveness and safety of menopause treatments: pitfalls of available evidence and future research need.
2024cited by 4position: contributordoi
Use of multiple covariates in assessing treatment-effect modifiers: A methodological review of individual participant data meta-analyses.
2024cited by 4position: contributordoi
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
2023cited by 60position: contributordoi
Estimating interactions and subgroup-specific treatment effects in meta-analysis without aggregation bias: A within-trial framework.
2023cited by 24position: contributordoi
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials
European Journal of Cancer 2023cited by 11position: middledoi
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials.
2023cited by 8position: contributordoi
A new approach to evaluating loop inconsistency in network meta-analysis.
2023cited by 7position: contributordoi
Germline variation in RASAL2 may predict survival in patients with RAS-activated colorectal cancer.
2023cited by 5position: contributordoi
Relationship between 233 colorectal cancer risk loci and survival in 1926 patients with advanced disease.
2023cited by 0position: contributordoi
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials.
2022cited by 93position: contributordoi
Association between time-to-treatment and outcomes in non-small cell lung cancer: a systematic review.
2022cited by 37position: contributordoi
Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis.
2022cited by 21position: contributordoi
Implications of analysing time-to-event outcomes as binary in meta-analysis: empirical evidence from the Cochrane Database of Systematic Reviews.
2022cited by 16position: contributordoi
Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer.
2022cited by 10position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Claire L. Vale · MRC Clinical Trials Unit at UCL20 papers (2019–2026)Sarah Burdett · MRC Clinical Trials Unit at UCL17 papers (2013–2025)Timothy S. Maughan · Oxford University Hospitals NHS Trust14 papers (2020–2025) · 12 papers (2020–2026)Mahesh Parmar · Tata Memorial Hospital10 papers (2019–2023)Louise Brown · North Manchester General Hospital9 papers (2020–2022)Ian R. White · Guy's and St Thomas' NHS Foundation Trust9 papers (2019–2024)Matt Seymour · Cancer Research UK Clinical Trials Unit8 papers (2020–2022)Phil Quirke · NIHR Leeds Musculoskeletal Biomedical Research Unit8 papers (2020–2022)Richard A. Adams · Northeast Georgia Medical Center8 papers (2020–2022)Richard Kaplan · University College London7 papers (2020–2022)Richard H. Wilson · Olema Pharmaceuticals (United States)5 papers (2021–2022)Srinivas Murthy · University of Bari Aldo Moro5 papers (2020–2026) · 5 papers (2020–2022)Mahesh Parmar · MRC Clinical Trials Unit at UCL5 papers (2013–2025)Laurence Collette · European Association of Urology4 papers (2013–2025)Jonathan Sterne · Office of the Director4 papers (2020–2025)Jayne Tierney · University College London4 papers (2020–2024)H. Wasan · National Health Service4 papers (2021–2022)Matthew R. Sydes · NHS England4 papers (2019–2025)